| Fick Eyecare, Inc | |
|
32 Tygart Mall Rd, Inside Walmart, Fairmont, WV 26554 | |
| (304) 366-3425 | |
| Not Available |
| Full Name | Fick Eyecare, Inc |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 32 Tygart Mall Rd, Fairmont, West Virginia |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053473827 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Primary |
| Provider Name | James M Fick |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1942386958 PECOS PAC ID: 8729170055 Enrollment ID: I20070816000516 |
News Archive
Following a heart attack or other heart trauma, the heart is unable to replace its dead cells. Patients are often left with little option other than heart transplants, which are rarely available, or more recently cell therapies that transplant heart cells into the patient's heart. In far too many cases, however, the transplanted heart cells do not engraft well, resulting in poor recovery.
Extended lymph node dissection – a treatment for gastric cancer involving the surgical removal of lymph nodes near the tumor, in distant areas of the stomach, and in some cases, in combination with the removal of the spleen and pancreas tail – has shown no long-term survival benefit for gastric cancer patients, according to the largest randomized trial of limited and extended lymph node dissection among this population.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pharma") announced today that they have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization and preclinical development with 3SBio's proven drug development and commercialization capabilities in China.
Merck & Co., Inc. has launched SAFLUTAN® (tafluprost) in the United Kingdom and Spain, and additional launches in other countries are expected over the next several months, pending regulatory approvals, the Company said today. SAFLUTAN is a preservative free, synthetic analogue of the prostaglandin F2α for the reduction of elevated intraocular pressure (IOP) in appropriate patients with primary open-angle glaucoma and ocular hypertension.
› Verified 3 days ago
| Provider Name | Tonya Marie Umbel |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1205199247 PECOS PAC ID: 5193958353 Enrollment ID: I20170519001488 |
News Archive
Following a heart attack or other heart trauma, the heart is unable to replace its dead cells. Patients are often left with little option other than heart transplants, which are rarely available, or more recently cell therapies that transplant heart cells into the patient's heart. In far too many cases, however, the transplanted heart cells do not engraft well, resulting in poor recovery.
Extended lymph node dissection – a treatment for gastric cancer involving the surgical removal of lymph nodes near the tumor, in distant areas of the stomach, and in some cases, in combination with the removal of the spleen and pancreas tail – has shown no long-term survival benefit for gastric cancer patients, according to the largest randomized trial of limited and extended lymph node dissection among this population.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pharma") announced today that they have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization and preclinical development with 3SBio's proven drug development and commercialization capabilities in China.
Merck & Co., Inc. has launched SAFLUTAN® (tafluprost) in the United Kingdom and Spain, and additional launches in other countries are expected over the next several months, pending regulatory approvals, the Company said today. SAFLUTAN is a preservative free, synthetic analogue of the prostaglandin F2α for the reduction of elevated intraocular pressure (IOP) in appropriate patients with primary open-angle glaucoma and ocular hypertension.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Fick Eyecare, Inc Po Box 5096, Whitehall Station, Fairmont, WV 26555-5096 Ph: (304) 366-3425 | Fick Eyecare, Inc 32 Tygart Mall Rd, Inside Walmart, Fairmont, WV 26554 Ph: (304) 366-3425 |
News Archive
Following a heart attack or other heart trauma, the heart is unable to replace its dead cells. Patients are often left with little option other than heart transplants, which are rarely available, or more recently cell therapies that transplant heart cells into the patient's heart. In far too many cases, however, the transplanted heart cells do not engraft well, resulting in poor recovery.
Extended lymph node dissection – a treatment for gastric cancer involving the surgical removal of lymph nodes near the tumor, in distant areas of the stomach, and in some cases, in combination with the removal of the spleen and pancreas tail – has shown no long-term survival benefit for gastric cancer patients, according to the largest randomized trial of limited and extended lymph node dissection among this population.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pharma") announced today that they have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization and preclinical development with 3SBio's proven drug development and commercialization capabilities in China.
Merck & Co., Inc. has launched SAFLUTAN® (tafluprost) in the United Kingdom and Spain, and additional launches in other countries are expected over the next several months, pending regulatory approvals, the Company said today. SAFLUTAN is a preservative free, synthetic analogue of the prostaglandin F2α for the reduction of elevated intraocular pressure (IOP) in appropriate patients with primary open-angle glaucoma and ocular hypertension.
› Verified 3 days ago
Fairmont Eye Care Inc Optometrist Medicare: Medicare Enrolled Practice Location: 709 Morgantown Ave, Fairmont, WV 26554 Phone: 304-366-4721 Fax: 304-366-4847 | |
Vision By Design Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1476 Lawrence St, Fairmont, WV 26554 Phone: 304-444-5573 | |
Vision Health Care, Inc. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 717 Fairmont Ave, Fairmont, WV 26554 Phone: 304-366-3830 Fax: 304-366-8049 | |
Dr. J Keith Wade, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 405 Locust Ave, Fairmont, WV 26554 Phone: 304-366-2020 Fax: 304-367-0863 | |
Dr. C David Laughlin, OD Optometrist Medicare: Medicare Enrolled Practice Location: 405 Locust Ave, Fairmont, WV 26554 Phone: 304-366-2020 Fax: 304-367-0863 | |
Dr. Hailey Long, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 709 Morgantown Ave, Fairmont, WV 26554 Phone: 304-366-4721 |